<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04156984</url>
  </required_header>
  <id_info>
    <org_study_id>2019-001G</org_study_id>
    <nct_id>NCT04156984</nct_id>
  </id_info>
  <brief_title>Comparison of Two Different Golimumab Dosing Regimens for Ulcerative Colitis</brief_title>
  <official_title>Exposure-response of Golimumab During Maintenance in Ulcerative Colitis: An Exploratory Pharmacokinetics/Pharmacodynamics Comparison of Different Dose Regimens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>David Drobne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Centre Ljubljana</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Partial response or loss of response to golimumab is observed in a significant proportion of
      patients started on golimumab for active ulcerative colitis. The current dosing regimen in
      European Union is based on patients' body weight as maintenance treatment for patients with ≥
      80 kg is 100 mg q4 weeks and for patients with &lt;80 kg 50 mg q4 weeks. The investigators
      recent observations in a golimumab pharmacokinetics study of 24 patients however, show large
      interindividual variations in golimumab trough concentrations. Furthermore, it seems that
      patients with continuous response have higher golimumab trough levels at several time points
      during treatment compared to patients who lose response. Higher induction/maintenance dose of
      golimumab increases golimumab trough levels, therefore it is likely that higher
      induction/maintenance dose of golimumab would increase efficacy of golimumab treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Partial response or loss of response to golimumab is observed in a significant proportion of
      patients started on golimumab for active ulcerative colitis. The current dosing regimen in
      European Union is based on patients' body weight as maintenance treatment for patients with ≥
      80 kg is 100 mg q4 weeks and for patients with &lt;80 kg 50 mg q4 weeks. The investigators
      recent observations in a golimumab pharmacokinetics study of 24 patients however, show large
      interindividual variations in golimumab trough concentrations. Furthermore, it seems that
      patients with continuous response have higher golimumab trough levels at several time points
      during treatment compared to patients who lose response. Higher induction/maintenance dose of
      golimumab increases golimumab trough levels, therefore it is likely that higher
      induction/maintenance dose of golimumab would increase efficacy of golimumab treatment.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2020</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endoscopic outcome</measure>
    <time_frame>50 weeks</time_frame>
    <description>Number of participants with mucosal healing at week 14 and week 50 on flexible rectosigmoidoscopy (recorded and assessed centrally by blinded reader if possible). Mucosal healing is defined as Mayo endoscopic score 0 or 1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical outcome</measure>
    <time_frame>50 weeks</time_frame>
    <description>Number of participants in clinical remission at week 14, week 26, week 38 and week 50. Clinical remission is defined as PRO-2 (Patient-Reported Outcome) score 0 (no rectal bleeding and no diarrhea/altered bowel habit).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of golimumab through levels and Anti-golimumab antibodies development on endoscopic and clinical outcome.</measure>
    <time_frame>50 weeks</time_frame>
    <description>Measurement of golimumab through levels. Blood withdrawals will be preformed at prespecified time points in all patients: week 0, week 2, week 4, week 6, week 10, week 14, week 26, week 38 and week 50.
Measurement of Anti-golimumab antibodies development. Blood withdrawals will be preformed at prespecified time points in all patients: week 2, week 4, week 6, week 10, week 14, week 26, week 38 and week 50.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Measurement of physical, social, and emotional status with The Short Inflammatory Bowel Disease Questionnaire.</measure>
    <time_frame>50 weeks</time_frame>
    <description>The Short Inflammatory Bowel Disease Questionnaire (SIBDQ) is a health-related quality of life (HRQoL) tool measuring physical, social, and emotional status (score 10-70, poor to good HRQoL). The questionnaire will be answered at week 0, week 6, week 14, week 26, week 38, week 50.</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v4.0.</measure>
    <time_frame>50 weeks.</time_frame>
    <description>Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Study arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects treated with optimized dose of golimumab, irrespective of weight: golimumab 200 mg sc, followed by 100 mg sc at week 2 and then 100 mg sc q4 weeks. In case of disease flare: discontinuation of drug.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects treated according to current European Label (2019) based on body weight:
&lt;80kg: golimumab 200 mg sc, followed by 100 mg sc at week 2 and then 50 mg sc q4wk. In case of disease flare (defined as PRO-2 ≥1): dose optimization to 100 mg sc q4wk starting at week 6 or at any time during first year.
≥80kg: golimumab 200 mg sc, followed by 100 mg sc at week 2 and then 100 mg sc q4wk. In case of disease flare (defined as PRO-2 ≥1): discontinuation of drug.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Golimumab Prefilled Syringe</intervention_name>
    <description>See arm description</description>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_label>Study arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed ulcerative colitis

        Exclusion Criteria:

          -  Active tuberculosis or other opportunistic bacterial, viral and fungal infections

          -  History of moderate to severe heart failure (NYHA III/IV), and potential risk of
             congestive heart failure

          -  Pregnancy

          -  History of allergic reactions to sorbitol (E420), L-histidine, L-histidine
             monohydrochloride monohydrate, polysorbate80, water for injections.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Drobne, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Centre Ljubljana</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Borut Štabuc, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University Medical Centre Ljubljana</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Drobne, MD, PhD</last_name>
    <phone>+38615221552</phone>
    <email>david.drobne@kclj.si</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sanjo Finderle, MD</last_name>
    <phone>+38615222639</phone>
    <email>sanjo.finderle@kclj.si</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>General hospital Celje, Department of Gastoenterology</name>
      <address>
        <city>Celje</city>
        <zip>3000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
    <contact>
      <last_name>Renata Šibli, MD,</last_name>
      <phone>+38634233441</phone>
      <email>renata.sibli@guest.arnes.si</email>
    </contact>
    <investigator>
      <last_name>Renta Šibli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>General hospital Izola, Department of Internal medicine</name>
      <address>
        <city>Izola</city>
        <zip>6310</zip>
        <country>Slovenia</country>
      </address>
    </facility>
    <contact>
      <last_name>Tamara Marušič, MD</last_name>
      <phone>+38656606551</phone>
      <email>tamara.marusic@sb-izola.si</email>
    </contact>
    <investigator>
      <last_name>Tamara Marušič, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Centre Ljubljana, Department of Gastroenterology</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
    <contact>
      <last_name>David Drobne, MD, PhD</last_name>
      <phone>+38615221552</phone>
      <email>david.drobne@kclj.si</email>
    </contact>
    <contact_backup>
      <last_name>Sanjo Finderle, MD</last_name>
      <phone>+38615222639</phone>
      <email>sanjo.finderle@kclj.si</email>
    </contact_backup>
    <investigator>
      <last_name>David Drobne, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Borut Štabuc, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sanjo Finderle, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Centre Maribor, Department of Gastoenterology</name>
      <address>
        <city>Maribor</city>
        <zip>2000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
    <contact>
      <last_name>Andreja Ocepek, MD</last_name>
      <phone>+38623212348</phone>
      <email>andreja.ocepek@ukc-mb.si</email>
    </contact>
    <investigator>
      <last_name>Andreja Ocepek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Slovenia</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 24, 2019</study_first_submitted>
  <study_first_submitted_qc>November 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2019</study_first_posted>
  <last_update_submitted>March 24, 2020</last_update_submitted>
  <last_update_submitted_qc>March 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Centre Ljubljana</investigator_affiliation>
    <investigator_full_name>David Drobne</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Safety</keyword>
  <keyword>Golimumab</keyword>
  <keyword>Reactive dose optimisation</keyword>
  <keyword>Proactive dose optimisation</keyword>
  <keyword>Golimumab concentration</keyword>
  <keyword>Mucosal healing</keyword>
  <keyword>Therapeutic drug monitoring</keyword>
  <keyword>Inflammatory bowel disease</keyword>
  <keyword>Personalized medicine</keyword>
  <keyword>Comparisons of European with US label</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

